



Corporate Round Table

Sept 7th 2018; 1pm-4pm, Cape Elizabeth, Maine

**Headache Cooperative of New England (HCNE) and Rhoyme Traylor, MBA, US
Advocacy Director, Amgen (neuroscience)**

Present: Drs Tom Ward, Alan Rapoport, Randy Weeks, Steve Baskin, Brian McGeeney, Peter McAllister, Paul Rizzoli, Herbert Markley, Robert Shapiro, Barbara Nye

Mr. Traylor, on behalf of Amgen, was thanked by the board of HCNE for helping support HCNE efforts to promote awareness and education in Headache Medicine. It was acknowledged that this is the second official meeting between Rhoyme Traylor and HCNE board members, the first meeting being August 2017.

The Headache Cooperative of New England presented a CME in Boston covering the monoclonal antibodies on November 5th 2017, lasting a couple of hours in one day, the day after the HCNE Boston CME event. The program was successful, and Amgen provided funding. HCNE noted that the timing of the event was very tight, given agreement for funding occurred not long before the actual event.

A central discussion point brought up by Mr. Traylor was exploring what activities in education would HCNE be interesting in pursuing that might be open to funding by Amgen. HCNE board members discussed the feasibility of separate CME programs and the structure and location, such as evening events, half day events, full day and 2-day CME events. Events for the public, and material developed for the public around migraine was discussed. Considerable time was spent brainstorming these topics.

Mr. Traylor noted patient advocacy events over the last year, as evidence that advocacy for Headache Medicine is growing. HCNE is planning a few lectures to the public at their upcoming CME event in Boston, November 2018. A miles for migraine run (to raise money for migraine related causes) is occurring that morning.

The board expressed frustration at resources needed to meet paperwork requirements surrounding the prescribing of Aimovig; such as prior approval forms for instance. On the Amgen side there appeared to be a mismatch between demand for the treatment and Amgen resources, which has been fixed. Mr. Traylor was asked to follow up with HCNE in connection with the precise reason Amgen does not allow Massachusetts residents participate in their 2-month free medication program. We understand it is due to Amgen's interpretation of Massachusetts law.

Summarized by Brian E McGeeney, MD, MPH, MBA

Secretary of HCNE.